Heron Therapeutics Inc

Research Heron Therapeutics Inc (HRTX) on Bullrun: market cap USD 60.63M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 60.63M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 154.90M-USD 20.00M-USD 27.91M73.3%-0.12USD 28.65MUSD 140.64MUSD 14.33M
FY2024USD 144.29M-USD 14.00M-USD 24.24M73.2%-0.09USD 25.80MUSD 177.76M-USD 33.65M
FY2023USD 127.04M-USD 111.00M-USD 60.33M48.8%-0.8USD 28.68MUSD 179.63M-USD 33.97M
FY2022USD 107.67M-USD 182.00M-USD 148.74M49.0%-1.67USD 15.36MUSD 158.51MUSD 13.57M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 60.63Mn/an/an/a
20252025-12-31USD 244.81Mn/an/an/a
20242024-12-31USD 232.76Mn/an/an/a
20232023-12-29USD 255.12Mn/an/an/a
20222022-12-30USD 297.22Mn/an/an/a
20212021-12-31USD 931.31Mn/an/an/a

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Heron Therapeutics Inc's market cap?

Heron Therapeutics Inc's market capitalization is USD 60.63M.

What does Heron Therapeutics Inc do?

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.